8-K: STAAR Surgical Reports Strong Q2 2026 Results

STAAR Surgical Company announced robust second quarter 2026 financial results, featuring a 111% year-over-year increase in net sales to $93.5 million and a significant swing to a net income of $8.1 million.

Summary

• STAAR Surgical reported a substantial increase in net sales for the second quarter ended July 3, 2026, reaching $93.5 million, an 111% rise compared to the prior year.
• Net income for the quarter was $8.1 million, or $0.16 per diluted share, a significant improvement from a net loss of $16.8 million in the same period last year.
• Adjusted EBITDA was $20.0 million, or $0.39 per diluted share, a strong turnaround from an Adjusted EBITDA loss of $14.8 million in the prior year.
• Sales in China were $52.3 million, showing over 100% growth year-over-year and 10% sequentially, contributing significantly to the overall results.
• APAC sales grew by 189% year-over-year, while Americas sales increased by 12% year-over-year.
• Gross margin improved to 74.5% from 74.0% in the prior year.
• The company ended the quarter with $181.5 million in cash, cash equivalents, and investments available for sale.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strongly positive report, with significant year-over-year growth in sales and a substantial turnaround from a net loss to net income, driven by strong performance in key international markets.

Positives

• Net sales surged by 111% year-over-year to $93.5 million.
• Turnaround from a net loss of $16.8 million to a net income of $8.1 million.
• Significant improvement in Adjusted EBITDA, moving from a loss of $14.8 million to a gain of $20.0 million.
• Strong growth in China with sales up over 100% year-over-year to $52.3 million.
• Robust performance in the APAC region, with sales up 189% year-over-year.
• Americas region demonstrated solid growth of 12% year-over-year.
• Gross margin improved to 74.5%, indicating better cost management and pricing power.
• Cash position strengthened to $181.5 million.

Negatives

• EMEA region sales declined by 1% year-over-year, primarily due to turmoil in the Middle East.
• Tariff expenses on U.S.-manufactured products sold to China are impacting margins until full manufacturing shifts to Switzerland.

Risks

• Reliance on independent distributors in international markets.
• Potential slowdown or disruption to the Chinese economy.
• Global economic and geopolitical conditions.
• Disruptions in the supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes, including tariffs.
• Competition in the refractive surgery market.
• Potential losses due to product liability claims.

Future Outlook

The company anticipates continued demand dynamics throughout the remainder of the year. While Q3 typically sees a step down from the first half peak in China, strong year-over-year growth is expected, excluding a one-time order in Q3 2025. Q4 is also planned for year-over-year growth, despite being a seasonally softer period. The company is focused on accelerating the development of its product pipeline with next-generation products.

Management Comments

• "We delivered strong financial performance in the second quarter, centered on our core pillars of revenue growth, increasing profitability, and accelerating innovation."
• "Our second quarter results reflect tangible progress across these key areas, with revenue, gross margin and net income all growing both year-over-year and sequentially."
• "We successfully navigated the complexities of our ERP cutover while maintaining our focus on efficiency and growth."
• "The refractive surgery market has undergone significant change over the last few years, and STAAR has emerged from that period stronger, more focused, and with clear momentum."

Industry Context

StockSavvy.ai notes that STAAR Surgical's strong performance aligns with the broader trend of increasing adoption of lens-based refractive surgery as an alternative to laser-based procedures, particularly in key international markets like China and Japan. The company's focus on myopia correction is also highly relevant given the global increase in myopia prevalence.

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, improved profitability, and a strong turnaround from net loss to net income, potentially leading to increased shareholder value.
• Patients: Benefit from advanced vision correction solutions (EVO ICL) that offer an alternative to glasses, contact lenses, and laser surgery, with improved outcomes and potentially wider accessibility.
• Surgeons/Hospitals: Opportunity to expand revenue streams with a profitable lens-based refractive surgery option, supported by company training programs.
• Employees: Potential for company growth and stability, though some workforce reductions in global marketing were noted.

Next Steps

• Continue to drive EVO+ adoption and overall EVO ICL procedure volume in China.
• Focus on increasing market share in China from laser-based procedures.
• Expand surgeon training programs across the Americas and globally.
• Continue to invest in direct-to-consumer awareness activities in Japan.
• Recruit a new Chief Technology Officer to lead the innovation agenda.
• Prepare for first-in-human studies of next-generation products.
• Shift 100% of products shipped to China to be manufactured in Switzerland by the end of 2026 to mitigate tariff impacts.

Key Dates

Recommendation

The filing demonstrates exceptionally strong year-over-year growth in sales and a significant turnaround in profitability, exceeding expectations. Key international markets, particularly China, are showing robust performance and market share gains. The company's strategic investments in innovation and operational efficiency, coupled with a strong cash position, position it for continued growth. The positive momentum and clear execution on strategic priorities warrant a strong buy recommendation.

Keywords

STAAR Surgical, EVO ICL, Phakic IOLs, Vision Correction, Refractive Surgery, Myopia, Ophthalmic Surgery, China Sales